Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1178

1.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Malm H, Klaukka T, Neuvonen PJ.

Obstet Gynecol. 2005 Dec;106(6):1289-96.

PMID:
16319254
2.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
3.

Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT.

Br J Clin Pharmacol. 2008 Apr;65(4):600-6. Epub 2007 Oct 22.

4.

Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.

Lund N, Pedersen LH, Henriksen TB.

Arch Pediatr Adolesc Med. 2009 Oct;163(10):949-54. doi: 10.1001/archpediatrics.2009.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1143.

PMID:
19805715
5.

Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.

El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H.

Arch Gen Psychiatry. 2012 Jul;69(7):706-14. doi: 10.1001/archgenpsychiatry.2011.2333.

PMID:
22393202
6.

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium..

Pediatrics. 2007 Apr;119(4):e900-6. Epub 2007 Mar 12.

PMID:
17353299
7.

Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study..

N Engl J Med. 2007 Jun 28;356(26):2684-92.

8.

Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study.

Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sørensen HT.

Scand J Infect Dis. 2003;35(4):255-9.

PMID:
12839155
9.

Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.

Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M.

J Clin Psychopharmacol. 2012 Apr;32(2):186-94. doi: 10.1097/JCP.0b013e3182490eaf.

PMID:
22367660
10.

Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors.

Pawluski JL, Galea LA, Brain U, Papsdorf M, Oberlander TF.

Pediatrics. 2009 Oct;124(4):e662-70. doi: 10.1542/peds.2009-0442. Epub 2009 Sep 28.

PMID:
19786426
11.

The recurrence risk of adverse outcome in the second pregnancy in women with rheumatic disease1.

Skomsvoll JF, Baste V, Irgens LM, Østensen M.

Obstet Gynecol. 2002 Dec;100(6):1196-202.

PMID:
12468163
12.

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.

Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernández S, Botet F, Gelabert E, Subirà S, Plaza A, Valdés M, Martin-Santos R.

J Affect Disord. 2011 Dec;135(1-3):208-15. doi: 10.1016/j.jad.2011.07.022. Epub 2011 Sep 3.

PMID:
21890210
13.

Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Nørgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B.

BMJ. 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012.

14.

MOS HIP: McMaster outcome study of hypertension in pregnancy.

Ray JG, Burrows RF, Burrows EA, Vermeulen MJ.

Early Hum Dev. 2001 Sep;64(2):129-43.

PMID:
11440825
15.

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.

J Clin Psychiatry. 2004 Feb;65(2):230-7.

PMID:
15003078
16.

Impact of police-reported intimate partner violence during pregnancy on birth outcomes.

Lipsky S, Holt VL, Easterling TR, Critchlow CW.

Obstet Gynecol. 2003 Sep;102(3):557-64.

PMID:
12962943
17.

Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy.

Viinikainen K, Heinonen S, Eriksson K, Kälviäinen R.

Epilepsia. 2006 Jan;47(1):186-92.

18.

High parity and fetal morbidity outcomes.

Aliyu MH, Salihu HM, Keith LG, Ehiri JE, Islam MA, Jolly PE.

Obstet Gynecol. 2005 May;105(5 Pt 1):1045-51.

PMID:
15863543
19.

Fetal outcomes of critically ill pregnant women admitted to the intensive care unit for nonobstetric causes.

Cartin-Ceba R, Gajic O, Iyer VN, Vlahakis NE.

Crit Care Med. 2008 Oct;36(10):2746-51.

PMID:
18828192
20.

First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27.

PMID:
17187388

Supplemental Content

Support Center